What is Sanara Medtech Inc's earnings per share (EPS)?

Sanara Medtech Inc (SMTI) reported diluted earnings per share of $-4.36 for fiscal year 2025. This represents a -282.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sanara Medtech Inc Financials

SMTI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Sanara Medtech Inc (SMTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SMTI FY2025 2026-04-22

Sanara’s high-gross-margin model now hinges less on product cost and more on absorbing SG&A as revenue scales.

By FY2025, net income reached $37.6M, but operating income was only $7.3M; the headline profit therefore overstates what the core business itself produced. Operating cash flow of $6.8M and free cash flow of $2.2M show the operation finally turned cash-generative, but at a level much closer to operating profit than to reported earnings.

The clearest operating change is fixed-cost absorption: revenue moved from $65.0M to $103.1M between FY2023 and FY2025, while SG&A did not keep pace. That let operating margin move from -6.5% to 7.1%, which means scale is now doing more of the profitability work than product-cost reduction.

The balance-sheet posture has shifted sharply toward debt funding: debt to equity rose from 0.2x in FY2023 to 7.7x in FY2025 as equity became thin. Near-term liquidity still looks serviceable because cash was $16.6M and the current ratio was 1.8x, so the pressure is more about capital structure than immediate bill-paying ability.

Financial Health Signals

Financial Profile 44/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Sanara Medtech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Sanara Medtech Inc has an operating margin of 7.1%, meaning the company retains $7 of operating profit per $100 of revenue. This below-average margin results in a low score of 28/100, suggesting thin profitability after operating expenses. This is up from 1.5% the prior year.

Growth

Sanara Medtech Inc's revenue surged 19.0% year-over-year to $103.1M, reflecting rapid business expansion. This strong growth earns a score of 77/100.

Leverage

Sanara Medtech Inc has elevated debt relative to equity (D/E of 7.74), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Sanara Medtech Inc's current ratio of 1.80 indicates adequate short-term liquidity, earning a score of 32/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Sanara Medtech Inc's free cash flow margin of 2.1% results in a low score of 25/100. Capital expenditures of $4.6M absorb a large share of operating cash flow.

Returns

100

Sanara Medtech Inc earns a strong 632.5% return on equity (ROE), meaning it generates $633 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 24.5% the prior year.

Altman Z-Score Grey Zone

2.17

Sanara Medtech Inc scores 2.17, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($181.5M) relative to total liabilities ($67.0M). This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

5/9

Sanara Medtech Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.18x

For every $1 of reported earnings, Sanara Medtech Inc generates $0.18 in operating cash flow ($6.8M OCF vs $37.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

1.1x

Sanara Medtech Inc earns $1.1 in operating income for every $1 of interest expense ($7.3M vs $6.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$103.1M

YoY+19.0%

5Y CAGR+45.9%

10Y CAGR+40.8%

Sanara Medtech Inc generated $103.1M in revenue in fiscal year 2025. This represents an increase of 19.0% from the prior year.

EBITDA

$11.3M

YoY+82.0%

Sanara Medtech Inc's EBITDA was $11.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 82.0% from the prior year.

Net Income

$37.6M

YoY+288.7%

Sanara Medtech Inc reported $37.6M in net income in fiscal year 2025. This represents an increase of 288.7% from the prior year.

EPS (Diluted)

$-4.36

YoY-282.5%

Sanara Medtech Inc earned $-4.36 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 282.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$2.2M

YoY+1041.1%

Sanara Medtech Inc generated $2.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 1041.1% from the prior year.

Cash & Debt

$16.6M

YoY+4.4%

5Y CAGR+105.2%

10Y CAGR+57.0%

Sanara Medtech Inc held $16.6M in cash against $46.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+2.2%

5Y CAGR+7.3%

10Y CAGR-22.0%

Sanara Medtech Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 2.2% from the prior year.

Margins & Returns

Gross Margin

92.7%

YoY+2.1pp

5Y CAGR+3.1pp

10Y CAGR+19.2pp

Sanara Medtech Inc's gross margin was 92.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the prior year.

Operating Margin

7.1%

YoY+5.6pp

5Y CAGR+39.4pp

10Y CAGR+35.7pp

Sanara Medtech Inc's operating margin was 7.1% in fiscal year 2025, reflecting core business profitability. This is up 5.6 percentage points from the prior year.

Net Margin

36.4%

YoY+25.3pp

5Y CAGR+65.0pp

10Y CAGR+76.2pp

Sanara Medtech Inc's net profit margin was 36.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 25.3 percentage points from the prior year.

Return on Equity

632.5%

YoY+608.0pp

5Y CAGR+704.8pp

Sanara Medtech Inc's ROE was 632.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 608.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.1M

YoY+79.3%

5Y CAGR+163.2%

Sanara Medtech Inc invested $5.1M in research and development in fiscal year 2025. This represents an increase of 79.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4.6M

YoY+2147.1%

5Y CAGR+53.4%

10Y CAGR+96.7%

Sanara Medtech Inc invested $4.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2147.1% from the prior year.

SMTI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$103.1M+19.0%	$86.7M+33.4%	$65.0M+41.8%	$45.8M+89.9%	$24.1M+54.9%	$15.6M
Cost of Revenue	$7.5M-7.6%	$8.1M+3.7%	$7.9M+23.5%	$6.4M+175.2%	$2.3M+43.0%	$1.6M
Gross Profit	$95.6M+21.7%	$78.5M+37.4%	$57.1M+44.7%	$39.5M+80.8%	$21.8M+56.3%	$14.0M
R&D Expenses	$5.1M+79.3%	$2.8M-31.5%	$4.1M+22.7%	$3.4M+502.7%	$559K+1290.2%	$40K
SG&A Expenses	$78.7M+9.8%	$71.7M+25.8%	$57.0M+24.0%	$46.0M+63.9%	$28.1M+50.2%	$18.7M
Operating Income	$7.3M+480.3%	$1.3M+129.9%	-$4.2M+66.3%	-$12.5M-69.7%	-$7.4M-46.5%	-$5.0M
Interest Expense	$6.8M+116.1%	$3.1M+557.5%	$476K+67.1%	$285K+39948.7%	$711-93.8%	$12K
Income Tax	N/A	$48K	N/A	-$5.8M	N/A	$0
Net Income	$37.6M+288.7%	$9.7M+124.6%	$4.3M+154.2%	-$7.9M-0.2%	-$7.9M-78.2%	-$4.4M
EPS (Diluted)	$-4.36-282.5%	$-1.14-119.2%	$-0.52+48.0%	$-1.00	N/A	$-0.76

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$27.5M+4.5%	$26.3M+1.9%	$25.8M+10.2%	$23.4M-10.9%	$26.3M+21.4%	$21.7M+7.5%	$20.2M+8.8%	$18.5M
Cost of Revenue	$1.9M0.0%	$1.9M-3.3%	$1.9M+5.6%	$1.8M-18.4%	$2.2M+12.9%	$2.0M-0.8%	$2.0M+6.3%	$1.9M
Gross Profit	$25.6M+4.8%	$24.5M+2.4%	$23.9M+10.6%	$21.6M-10.2%	$24.1M+22.2%	$19.7M+8.4%	$18.2M+9.0%	$16.6M
R&D Expenses	$1.7M+62.3%	$1.0M-18.1%	$1.3M+12.9%	$1.1M+887.1%	$113K-85.6%	$784K-20.5%	$986K+4.2%	$946K
SG&A Expenses	$15.8M-20.3%	$19.9M-7.8%	$21.6M+0.5%	$21.4M+12.2%	$19.1M+9.7%	$17.4M-8.1%	$19.0M+17.1%	$16.2M
Operating Income	$6.5M+120.1%	$2.9M+9482.5%	-$31K+98.5%	-$2.1M-142.5%	$4.9M+529.0%	$779K+127.0%	-$2.9M-88.3%	-$1.5M
Interest Expense	$1.8M+0.8%	$1.8M+1.5%	$1.8M+36.0%	$1.3M+2.2%	$1.3M+39.0%	$928K+44.0%	$644K+141.0%	$267K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$73.5M+341.7%	-$30.4M-1409.7%	-$2.0M+42.9%	-$3.5M-119.8%	$17.8M+722.5%	-$2.9M+18.4%	-$3.5M-98.6%	-$1.8M
EPS (Diluted)	N/A	$-3.40-1378.3%	$-0.23+43.9%	$-0.41	N/A	$-0.34+17.1%	$-0.41-95.2%	$-0.21

SMTI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$72.9M-17.2%	$88.1M+19.3%	$73.9M+21.0%	$61.0M+67.7%	$36.4M+270.4%	$9.8M
Current Assets	$33.5M+0.7%	$33.3M+75.2%	$19.0M-7.8%	$20.6M-16.2%	$24.6M+449.0%	$4.5M
Cash & Equivalents	$16.6M+4.4%	$15.9M+208.5%	$5.1M-42.5%	$9.0M-52.0%	$18.7M+3996.2%	$455K
Inventory	$3.9M+43.4%	$2.8M-41.6%	$4.7M+32.9%	$3.5M+73.3%	$2.0M+78.4%	$1.1M
Accounts Receivable	N/A	N/A	N/A	$6.8M+137.9%	$2.9M	$0
Goodwill	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M	N/A	N/A
Total Liabilities	$67.0M+36.3%	$49.2M+67.9%	$29.3M+51.6%	$19.3M+209.3%	$6.2M+56.7%	$4.0M
Current Liabilities	$18.6M+21.8%	$15.3M+11.1%	$13.8M+7.5%	$12.8M+112.6%	$6.0M+70.1%	$3.5M
Long-Term Debt	$46.0M+49.8%	$30.7M+236.8%	$9.1M	N/A	N/A	N/A
Total Equity	$5.9M-84.9%	$39.4M-12.1%	$44.8M+7.2%	$41.8M+36.5%	$30.6M+398.2%	$6.2M
Retained Earnings	-$75.3M-99.3%	-$37.8M-34.8%	-$28.0M-19.8%	-$23.4M-53.6%	-$15.2M-116.6%	-$7.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$72.9M+2.6%	$71.1M-28.0%	$98.8M+2.5%	$96.4M+9.4%	$88.1M-0.5%	$88.5M+20.7%	$73.4M+3.5%	$70.9M
Current Assets	$33.5M+7.4%	$31.2M-7.3%	$33.7M-8.6%	$36.8M+10.6%	$33.3M+4.4%	$31.9M+53.3%	$20.8M+21.1%	$17.2M
Cash & Equivalents	$16.6M+11.0%	$14.9M-11.9%	$17.0M-18.0%	$20.7M+30.3%	$15.9M-2.5%	$16.3M+164.7%	$6.2M+117.5%	$2.8M
Inventory	$3.9M+16.6%	$3.4M-3.6%	$3.5M+11.2%	$3.2M+14.8%	$2.8M-8.5%	$3.0M-15.6%	$3.6M-15.7%	$4.2M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M0.0%	$3.6M
Total Liabilities	$67.0M+3.2%	$64.9M+2.5%	$63.4M+6.1%	$59.7M+21.4%	$49.2M+0.2%	$49.1M+53.5%	$32.0M+14.6%	$27.9M
Current Liabilities	$18.6M+7.3%	$17.4M+16.7%	$14.9M+12.0%	$13.3M-13.1%	$15.3M+6.6%	$14.3M+24.0%	$11.6M-9.3%	$12.7M
Long-Term Debt	$46.0M+2.0%	$45.1M+2.0%	$44.2M+1.9%	$43.4M+41.4%	$30.7M+2.0%	$30.1M+109.3%	$14.4M+63.9%	$8.8M
Total Equity	$5.9M-3.4%	$6.1M-82.6%	$35.4M-3.5%	$36.7M-6.9%	$39.4M-1.0%	$39.8M-4.6%	$41.7M-3.7%	$43.3M
Retained Earnings	-$75.3M-2.2%	-$73.7M-70.2%	-$43.3M-4.8%	-$41.3M-9.3%	-$37.8M-4.2%	-$36.2M-8.6%	-$33.4M-11.7%	-$29.9M

SMTI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$6.8M+28634.4%	-$24K+99.3%	-$3.2M+41.6%	-$5.6M-15.4%	-$4.8M-19.3%	-$4.0M
Capital Expenditures	$4.6M+2147.1%	$206K-22.4%	$265K+80.4%	$147K-14.5%	$172K-68.4%	$544K
Free Cash Flow	$2.2M+1041.1%	-$230K+93.5%	-$3.5M+38.4%	-$5.7M-14.3%	-$5.0M-8.9%	-$4.6M
Investing Cash Flow	-$15.0M-126.5%	-$6.6M+35.2%	-$10.2M-190.7%	-$3.5M+33.6%	-$5.3M-92.6%	-$2.7M
Financing Cash Flow	$8.9M-48.8%	$17.4M+80.1%	$9.6M+1636.8%	-$627K-102.2%	$28.3M+4446.9%	$622K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$3.9M+81.3%	$2.2M-18.3%	$2.7M+233.3%	-$2.0M-314.5%	$932K-54.5%	$2.1M+245.2%	-$1.4M+11.4%	-$1.6M
Capital Expenditures	$82K-92.2%	$1.1M-39.8%	$1.8M+2.2%	$1.7M+2286.9%	$72K+693.4%	$9K-84.5%	$59K-10.7%	$66K
Free Cash Flow	$3.9M+245.8%	$1.1M+23.7%	$903K+124.3%	-$3.7M-532.8%	$860K-57.9%	$2.0M+238.8%	-$1.5M+11.4%	-$1.7M
Investing Cash Flow	-$2.4M+28.5%	-$3.4M+12.9%	-$3.9M+24.2%	-$5.2M-3884.7%	-$130K+98.0%	-$6.4M-10718.3%	-$59K+10.7%	-$66K
Financing Cash Flow	$139K+118.0%	-$775K+68.6%	-$2.5M-120.6%	$12.0M+1098.2%	-$1.2M-108.3%	$14.4M+201.1%	$4.8M+827.5%	-$659K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SMTI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	92.7%+2.1pp	90.6%+2.7pp	87.9%+1.8pp	86.1%-4.3pp	90.4%+0.8pp	89.6%
Operating Margin	7.1%+5.6pp	1.5%+7.9pp	-6.5%+20.8pp	-27.3%+3.2pp	-30.6%+1.8pp	-32.3%
Net Margin	36.4%+25.3pp	11.2%+4.5pp	6.6%+23.9pp	-17.3%+15.5pp	-32.8%-4.3pp	-28.5%
Return on Equity	632.5%+608.0pp	24.5%+14.9pp	9.6%+28.6pp	-19.0%+6.9pp	-25.9%+46.4pp	-72.3%
Return on Assets	51.5%+40.5pp	11.0%+5.1pp	5.8%+18.8pp	-13.0%+8.8pp	-21.8%+23.5pp	-45.2%
Current Ratio	1.80-0.4	2.18+0.8	1.38-0.2	1.61-2.5	4.09+2.8	1.27
Debt-to-Equity	7.74+7.0	0.78+0.6	0.20-0.3	0.46+0.3	0.20-0.4	0.65
FCF Margin	2.1%+2.4pp	-0.3%+5.1pp	-5.4%+7.0pp	-12.4%+8.2pp	-20.6%+8.7pp	-29.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	93.2%+0.3pp	92.9%+0.4pp	92.5%+0.3pp	92.2%+0.7pp	91.5%+0.6pp	90.8%+0.8pp	90.0%+0.2pp	89.8%
Operating Margin	23.5%+12.4pp	11.2%+11.3pp	-0.1%+8.8pp	-8.9%-27.5pp	18.6%+15.0pp	3.6%+17.9pp	-14.3%-6.0pp	-8.3%
Net Margin	267.1%+382.6pp	-115.5%-107.7pp	-7.8%+7.2pp	-15.0%-82.7pp	67.6%+80.8pp	-13.2%+4.2pp	-17.4%-7.9pp	-9.5%
Return on Equity	1238.0%+1732.5pp	-494.6%-488.9pp	-5.7%+3.9pp	-9.6%-54.8pp	45.1%+52.3pp	-7.2%+1.2pp	-8.4%-4.3pp	-4.1%
Return on Assets	100.8%+143.6pp	-42.8%-40.7pp	-2.0%+1.6pp	-3.7%-23.9pp	20.2%+23.4pp	-3.2%+1.5pp	-4.8%-2.3pp	-2.5%
Current Ratio	1.800.0	1.80-0.5	2.26-0.5	2.77+0.6	2.18-0.0	2.23+0.4	1.80+0.5	1.35
Debt-to-Equity	7.74+0.4	7.33+6.1	1.25+0.1	1.18+0.4	0.78+0.0	0.76+0.4	0.34+0.1	0.20
FCF Margin	14.0%+9.8pp	4.2%+0.8pp	3.5%+19.4pp	-15.9%-19.1pp	3.3%-6.2pp	9.4%+16.7pp	-7.3%+1.7pp	-9.0%

Similar Companies

Angiodynamics ANGO

$442.9M

Embecta Corp EMBC

$540.7M

KESTRA MED TECHNOLOGIES LTD KMTS

$1.4B

Stereotaxis Ord STXS

$187.2M

Orasure Tech OSUR

$218.4M

Frequently Asked Questions

What is Sanara Medtech Inc's annual revenue?

Sanara Medtech Inc (SMTI) reported $103.1M in total revenue for fiscal year 2025. This represents a 19.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sanara Medtech Inc's revenue growing?

Sanara Medtech Inc (SMTI) revenue grew by 19% year-over-year, from $86.7M to $103.1M in fiscal year 2025.

Is Sanara Medtech Inc profitable?

Yes, Sanara Medtech Inc (SMTI) reported a net income of $37.6M in fiscal year 2025, with a net profit margin of 36.4%.

What is Sanara Medtech Inc's EBITDA?

Sanara Medtech Inc (SMTI) had EBITDA of $11.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Sanara Medtech Inc have?

As of fiscal year 2025, Sanara Medtech Inc (SMTI) had $16.6M in cash and equivalents against $46.0M in long-term debt.

What is Sanara Medtech Inc's gross margin?

Sanara Medtech Inc (SMTI) had a gross margin of 92.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sanara Medtech Inc's operating margin?

Sanara Medtech Inc (SMTI) had an operating margin of 7.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Sanara Medtech Inc's net profit margin?

Sanara Medtech Inc (SMTI) had a net profit margin of 36.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Sanara Medtech Inc's return on equity (ROE)?

Sanara Medtech Inc (SMTI) has a return on equity of 632.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sanara Medtech Inc's free cash flow?

Sanara Medtech Inc (SMTI) generated $2.2M in free cash flow during fiscal year 2025. This represents a 1041.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sanara Medtech Inc's operating cash flow?

Sanara Medtech Inc (SMTI) generated $6.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sanara Medtech Inc's total assets?

Sanara Medtech Inc (SMTI) had $72.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sanara Medtech Inc's capital expenditures?

Sanara Medtech Inc (SMTI) invested $4.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Sanara Medtech Inc spend on research and development?

Sanara Medtech Inc (SMTI) invested $5.1M in research and development during fiscal year 2025.

How many shares does Sanara Medtech Inc have outstanding?

Sanara Medtech Inc (SMTI) had 9M shares outstanding as of fiscal year 2025.

What is Sanara Medtech Inc's current ratio?

Sanara Medtech Inc (SMTI) had a current ratio of 1.80 as of fiscal year 2025, which is generally considered healthy.

What is Sanara Medtech Inc's debt-to-equity ratio?

Sanara Medtech Inc (SMTI) had a debt-to-equity ratio of 7.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sanara Medtech Inc's return on assets (ROA)?

Sanara Medtech Inc (SMTI) had a return on assets of 51.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sanara Medtech Inc's Altman Z-Score?

Sanara Medtech Inc (SMTI) has an Altman Z-Score of 2.17, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Sanara Medtech Inc's Piotroski F-Score?

Sanara Medtech Inc (SMTI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sanara Medtech Inc's earnings high quality?

Sanara Medtech Inc (SMTI) has an earnings quality ratio of 0.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Sanara Medtech Inc cover its interest payments?

Sanara Medtech Inc (SMTI) has an interest coverage ratio of 1.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Sanara Medtech Inc?

Sanara Medtech Inc (SMTI) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.